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A B S T R A C T
Introduction: Rare genetic functional variants can contribute to 30-40% of functional variability in genes re-
levant to drug action. Therefore, we investigated the role of rare functional variants in antidepressant response.
Method: Mexican-American individuals meeting the Diagnostic and Statistical Manual-IV criteria for major
depressive disorder (MDD) participated in a prospective randomized, double-blind study with desipramine or
fluoxetine. The rare variant analysis was performed using whole-exome genotyping data. Network and pathway
analyses were carried out with the list of significant genes.
Results: The Kernel-Based Adaptive Cluster method identified functional rare variants in 35 genes sig-
nificantly associated with treatment remission (False discovery rate, FDR <0.01). Pathway analysis of these
genes supports the involvement of the following gene ontology processes: olfactory/sensory transduction, reg-
ulation of response to cytokine stimulus, and meiotic cell cycleprocess.
Limitations: Our study did not have a placebo arm. We were not able to use antidepressant blood level as a
covariate. Our study is based on a small sample size of only 65 Mexican-American individuals. Further studies
using larger cohorts are warranted.
Conclusion: Our data identified several rare functional variants in antidepressant drug response in MDD
patients. These have the potential to serve as genetic markers for predicting drug response. Trial registration:
ClinicalTrials.gov NCT00265291
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Major depressive disorder (MDD) represents a severe public health
challenge in the U.S. and worldwide, with a lifetime prevalence of 10-
20% in the general population (Wong and Licinio, 2001). Currently,
antidepressants are among the top prescribed drugs (Larura et al.,
2011). Thus, the ability to predict antidepressant response could have a
significant and substantial public health impact. However, recent meta-
analyses on pharmacodynamic pharmacogenetics of antidepressants in
MDD failed to show any variation of genome-wide significance
(Fabbri et al., 2013; Fabbri and Serretti, 2015; GENDEP et al., 2013;
Niitsu et al., 2013).
Common and rare variants contribute to common complex disease
heritability, and expanding evidence supports the significant role of
rare genetic variants in the etiology of complex diseases (Cohen et al.,
2004; Leblond et al., 2012; Liu and Leal, 2010b; Yu et al., 2018).
Human populations possess an abundance of rare genetic variants (once
every 17 bases) that cluster geographically; consequently, assembling a
complete rare variant catalog will be a formidable feat (Nelson et al.,
2012). An incipient drug response literature supports the notion that
the genetic architecture of drug efficacy likely mirrors that of complex
traits (Zhou and Pearson, 2013). Rare genetic variants have shown to
reduce protein levels by more than 70%, be responsible for drug-in-
duced severe toxicity/lethality, and contribute to 30-40% of functional
variability in pharmacogenetics genes, such as nuclear receptors, me-
tabolic enzymes, and cellular transporters (Del Re et al., 2016;
Kozyra et al., 2016; Wobst et al., 2016). Therefore, previously un-
reported rare functional variants may exert further impact on the
phenotype than common variations and may be crucial in the proble-
matic genotype/phenotype discordance influencing the analysis of
pharmacogenetic screening (Maggo et al., 2016).
Up until now, no gene has been identified to have a major effect in
antidepressant drug response in MDD. Using transcriptomics Hodgson
et al. (Hodgson et al., 2016) have recently shown that alterations in the
expression of the MMP28 and KXD1 genes in the blood were associated
with better response to nortriptyline. Polygenic risk scores have been
recently used to test whether they could predict symptom improvement
or remission. No significant predictive effect was found using polygenic
risk scores in pharmacogenetic studies and the genetic liability to MDD
(Garcia-Gonzalez et al., 2017).
Functional single nucleotide polymorphisms (SNPs) that result in
amino acid, regulatory, epigenetic, or splicing changes can have a
considerable impact on phenotype (Ng et al., 2009). In fact, significant
portions of the current missing heritability of complex traits may be due
to genetic interactions (Zuk et al., 2012). Here, we explored the premise
that rare functional SNPs influence to antidepressant drug response by
performing whole-genome screening. The goal of this line of study is to
provide a basis for future pharmacogenetics approaches aimed at using
genetic markers to predict treatment outcomes and to pave the foun-
dation for future personalized MDD treatment.
2. Materials and methods
2.1. Clinical study
Institutional Review Boards and Human Research Ethics
Committees approved the study protocol at the University of California
Los Angeles and the University of Miami in the USA, the Australian
National University and Bellbery Ltd in Australia, and the State
University of New York Upstate Medical University. The study was
registered in the public database clinicaltrials.gov, NCT00265291
(Dong et al., 2009; Wong et al., 2012; Wong et al., 2014). We obtained
written informed consent from all participants after oral and written
explanations of all study procedures were furnished to participants in
their preferred language (English or Spanish).
Briefly, in this single site treatment trial all subjects had
comprehensive psychiatric and medical assessments, and if enrolled,
participated in two consecutive study phases: 1) An initial 1-week
single-blind placebo lead-in phase to mitigate placebo responders, fol-
lowed by 2) Random assignment to fluoxetine 10-40 mg/day or desi-
pramine 50-200 mg/day treatment. As antidepressant medications are
efficacious MDD treatment, a placebo lead-in period followed by active
treatment for all patients was used to minimize human participants at
risk (Baldwin et al., 2003; Kim and Holloway, 2003). Participants had
weekly follow-up visits to assess their clinical status using clinical ob-
servations, interviews, and self-reports.
2.1.1. Participants
All subjects met four inclusion criteria: 1) Age between 18-70 years.
2) ≥ 3 out of 4 grandparents were born in Mexico (Hazuda et al.,
1986). 3) Diagnostic and Statistical Manual-IV diagnosis of a current
unipolar major depressive episode (APA, 1994). 4) 21-Item Hamilton
Depression Rating Scale (HAM-D) (Hamilton, 1960) score of ≥17 with
item #1 (depressed mood) rated ≥2 (Dong et al., 2009; Wong et al.,
2012; Wong et al., 2014). Our exclusion criteria included: 1) Active
medical illnesses that could be related to the current depressive epi-
sode. 2) Axis I disorder other than major depressive disorder or primary
anxiety disorders. 3) Active suicidal ideation or severe recent suicide
attempt. 4) Lack of contraception use in women of childbearing age, or
pregnant or lactating. 5) Electroconvulsive treatment within the last six
months; 6) Use of other antidepressant treatment or medications that
interfere with EEG or antidepressant treatment in last 2 weeks. 7)
Previous unsatisfactory response to desipramine or fluoxetine treat-
ment. 8) Illicit drug or alcohol abuse within the previous three months.
9) Presently receiving counseling or psychotherapy (Dong et al., 2009;
Wong et al., 2012; Wong et al., 2014).
2.1.2. Treatment
All subjects received an initial one-week of single-blind placebo to
reduce placebo responders (defined as subjects with a ≥ 25% decrease
in HAM-D score compared to the screening visit and or HAM-D score
less than 18). Remaining participants were then randomly assigned to
receive an 8-week double-blinded treatment with either fluoxetine or
desipramine in a 1:1 ratio. Initially, participants received either fluox-
etine 10 mg/day or desipramine 50 mg/day; doses increased respec-
tively to 20 mg/day or 100 mg/day at week 2 of active treatment. Dose
escalation schedule occurred as follows in subjects who tolerated the
previous dose: 1) The dose was increased to 30 mg/day for fluoxetine,
and 150 mg/day for desipramine at week 4 for participants who
showed less than a 25% decrease in their HAM-D scores. 2) A maximum
dose of 40 mg fluoxetine/200 mg desipramine was increased in parti-
cipants with HAM-D scores <12 at week 6. Each subject was assessed
according to the reduction in HAM-D score from week 0 to week 8. The
categorical outcome measures were as follow: remission for HAM-D
scores <8 and nonresponse for HAM-D score reduction of <50%. After
the 8-week double-blinded phase, participants were referred to a psy-
chiatric clinic of their choice to follow up treatment.
2.1.3. Clinical outcome measures
We determined the presence of a current major depressive episode
using the Structured Clinical Interview for Diagnosis (First et al., 1994)
either in English or in Spanish, and the DSM-IV diagnoses were further
confirmed by a research psychiatrist. The mean Kappa score among
raters ranged from 0.84-0.85 for sensitivity and specificity.
Experienced bilingual clinical personnel rated MDD symptom se-
verity weekly using the Spanish or English versions of the HAM-D
(Hamilton, 1960), Hamilton Anxiety Rating Scale (Hamilton, 1959),
Global Assessment Scale (Endicott et al., 1976), Beck Depression In-
ventory (Beck et al., 1961), and the Center for Epidemiological De-
pression Rating Scale (Roberts, 1980). Antidepressant drug levels were
obtained randomly to confirm treatment adherence.
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2.1.4. Genomic DNA collection
Blood samples from participants were collected into BD Vacutainer
EDTA tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Genomic




Whole-exome genotyping was performed using the Illumina®
HumanExome BeadChip-12v1_A, which has > 250,000 markers from
diverse populations and common conditions, including psychiatric
disorders, diabetes, and cancer. Genotyping reliability and quality were
tested using a duplicated sample was duplicated.
2.2.2. Quality Control and Rare and Functional Variants filtering
Samples with SNP call rates below 99% were excluded. We esti-
mated and used for quality control the Identity by Descent between all
pairs of individuals. Illumina's GenomeStudio data was used in SVS
7.6.7, Golden Helix® (Golden Helix, Inc. Bozeman, MT, USA (http://
www.goldenhelix.com), to extract genotyping data (such as genotype,
log ratio, computed copy number variation values, allele frequency,
etc). The following exclusion criteria were used: (i) deviations from the
Hardy-Weinberg equilibrium using P-values <0.05/m (m is the number
of markers included in the analyses), (ii) a genotype call rate of less
than 90%% and (iii) number of alleles different from 2. We used
maximum likelihood to estimate genotype and allelic frequencies; only
markers with minor allele frequency (MAF) < 0.01 in a larger ascer-
tained cohort of Mexican-Americans were used to define the criteria of
rareness for subsequent analysis (Wong et al., 2017).
2.2.3. Genetic Stratification Analysis
The inbreeding coefficient was estimated to detect the presence of
hidden biological relatives in the sample, as this may reduce the in-
dependence of the data. We estimated to evaluate the potential pre-
sence of genotype stratification (micro-differentiation) using the fixa-
tion index between pairs of subpopulations, case subjects, and controls,
by employing a set of autosomal independent markers. Additional
correction of putative population stratification was applied using 10
principal component analyses to normalize genotypic data by its actual
standard deviation.
2.2.4. Functional Variants Filtering and Classification
We used the information from the
dbNSFP_NS_Functional_Predictions annotation track (GRCh_37) to
identify variations with potential functional effect (Davydov et al.,
2010) employing SIFT, PolyPhen-2, Mutation Taster, Gerp++, and
PhyloP (Adzhubei et al., 2010; Ng and Henikoff, 2003; Schwarz et al.,
2010), to consider which variants were most likely to have functional
effects. The SVS 7.6.6, Golden Helix® Variant Classification module was
used to investigate the interactions among variants and gene transcripts
in order to categorize variants.
2.2.5. Rare Variant Analysis
We used the Kernel-Based Adaptive Cluster (KBAC) method, im-
plemented in Golden Helix®, which relates variant classification and
association testing. The rare variant data are collapsed within each of a
number of chromosomal regions into multi-marker genotypes. Because
variants are rare, only a relatively few different multi-marker genotypes
will be found in any given region, and their counts are used to perform
a distinct multivariate case/control test to ascertain their association
with the phenotype (Liu and Leal, 2010a, b). In the KBAC method,
genotypes with high sample risks are given higher weights, which can
potentially separate causal from non-causal genotypes. A one-sided test
was used due to the weighting procedure, the P-values were estimated
using 10,000 permutations, and correction for multiple comparisons
was performed using FDR (False discovery rate). Missing data were
imputed as a homozygous major allele (wild-type). This method is used
as implemented in SVS 7.6.7. that also implemented the mixed model to
the KBAC analysis to correct for genetic relationships among the sam-
ples. The test works as the KBAC with Regression but adapted to a lo-
gistic mixed-model equation. For the Kinship information, we estimated
the identity by state matrix (IBS) with 83,937 common, non-functional,
and redundant markers that were excluded from the final analysis.
2.3. Pathway and Network Analyses
We used ConsensusPathDB (Release 30) (Kamburov et al., 2011;
Kamburov et al., 2013), which is a freely available molecular functional
interaction database with a web interface, to evaluate potential
common ontogenetic or cellular processes and build networks with the
list of genes that were significantly associated to remission in the rare
variants analyses.
2.4. Brain Expression Quantitative trait loci (eQTL) Analyses
The UK Brain Expression Consortium (http://www.braineac.org/)
web-based server Brain eQTL Almanac was used to find a significant
statistical association between genetic polymorphisms and gene ex-
pression levels in the hippocampus and other brain areas
(Ramasamy et al., 2014).
3. Results
3.1. Participant characteristics and response of a prospective
pharmacogenetics
Our participants were mostly first-generation Spanish-speaking-only
Mexican-Americans of Los Angeles; a detailed description of this cohort
and treatment outcomes can be found elsewhere (Dong et al., 2009;
Wong et al., 2012; Wong et al., 2014). Briefly, no statistically significant
differences in demographic and baseline clinical characteristics were
found between desipramine- and fluoxetine-treated patients (Table S1).
In this study, 72% of patients (N=166) completed 8 weeks of treat-
ment, while 66 participants did not complete the study after receiving
at least one week of medication. A higher dropout rate was found in
patients treated with desipramine. Fluoxetine and desipramine were
effective in this population; however, fluoxetine-treated participants
had better scores at the end of the 8-week treatment in several rating
scales (HAM-D, Hamilton Anxiety Rating scale, Depression Inventory,
and Global Assessment Scale) than desipramine-treated patients. We
obtained and analyzed Illumina® HumanExome BeadChip-12v1_A data
from 65 participants - 36 remitters (17 desipramine- and 19 fluoxetine-
treated), and 29 non-responders (14 desipramine- and 15 fluoxetine-
treated). Demographic data and antidepressant treatment of remitters
and non-responders are provided in Table S2.
3.2. Power analysis
Consistent with our hypothesis that varianst of large effect (i.e.
mutations) modify antidepressant response in MDD, we performed a
power analyses to detect any such large effects (as defined by the
Cohen's d parameter). This analysis used small sample sizes
(Vélez et al., 2016). In previous work, we showed that 72 individuals
would be sufficient to detect up to 80% true positives with effect size
d=0.82 when m=100,000 variants are tested for association to a
quantitative trait (Fig. S1); this power analysis extrapolates to a cate-
gorical trait as demonstrated in Velez et al., supplementary material
(Vélez et al., 2016). The final number of tested variants was sig-
nificantly lower than 100,000, due to pruning of non-informative, and
common variants.
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3.3. Several rare variants were associated with antidepressant response
After filtering out markers that did not meet either quality control
criteria or variability requirements, and polymorphisms without po-
tential functional effect, 12,718 variants remained for rare variant
analysis (Fig. 1). Those variants were anchored in 7,863 genes and
categorized in 15 types according with their Sequence Ontology (Table
S3).
Using the KBAC method, we reported that rare variants in 35 genes
(Table 1) were significantly associated with remission of MDD symp-
toms (FDR ≤ 0.01). The rare variants examined that are likely to
contribute to treatment outcomes are listed in Table S4.
3.4. Pathway and network analyses
Table 2 summarizes the pathway and network findings. The top
gene ontology (GO) processes significantly associated with anti-
depressant remission were: 1) olfactory/sensory transduction, 2) reg-
ulation of response to cytokine stimulus, and 3) meiotic cell cycle
process (Table 2 and Fig. 2). Enriched pathway-based sets were sig-
nificant for olfactory/sensory transduction and signaling pathways and
transport of glucose and other sugars, bile salts and organic acids, metal
ions, and amine compounds (Table 2). The most significantly enriched
neighborhood-based entity set included ALG6 (ALG6, alpha-1,3-gluco-
syltransferase, Table 2. ALG6 is an important post-translation modifier;
it catalyzes the addition of the first glucose residue to the expanding
lipid-linked oligosaccharide precursor of the N-linked glycosylation, a
process by which glycosyl groups are added onto proteins in the en-
doplasmic reticulum membrane.
3.5. CWC22 variants significantly change eQTL in human brain areas
We considered that these results had strengthened the potential
association between the CWC22 gene and antidepressant remission, as
we previously listed that chromosome locus [Chr2q13.3/(exm)
rs16867321] among the top common SNPs likely associated with an-
tidepressant remission (Wong et al., 2014). As CWC22 variants may
represent a valid signal associated with antidepressant remission and
this gene is widely expressed in the brain (Allen Brain Atlas; www.
brain-map.org) (Lein et al., 2007), we queried the CWC22 gene on the
Braineac webserver and found that variants of this gene significantly
changed eQTL in all ten brain areas listed (Table S5). Nine listed var-
iants changed eQTL in the hippocampus (Table 3).
4. Discussion
Our rare variant analysis of whole-exome genotyping data identified
35 genes that were significantly associated with remission (FDR ≤
0.01), which is surprising given the small number of remitters (n=36)
and non-responders (n=29). Our Mexican-American cohort and
HapMap Mexican-American cohort were recruited from the same lo-
cation in Los Angeles; their estimated median ancestry proportions are
5% African, 45% Indigenous American, and 49% European,
(Johnson et al., 2011). Therefore, they contain increased numbers of
variants and rare variants because of their African and Spanish ances-
tries (Genomes Project et al., 2012; International HapMap et al., 2010).
We briefly summarized below the role of genes listed in Table 1 in
MDD susceptibility or antidepressant response.
1) METTL3, methyltransferase like 3 - Located in chromosome 1q24
METTL3 is associated with methyltransferase activity, which parti-
cipates in estrogen receptor-induced gene transcription (Green and
Galea, 2008), and higher DNA methylation in that region has been
observed in women with bipolar disorder and psychosis (Mill et al.,
2008). Genome-wide linkage on chromosome 1q21.3-q32.1 suggests
that this locus could modulate vulnerability to postpartum mood
symptoms and postpartum psychosis (Mahon et al., 2009; Pinna and
Zompo, 2012; Thippeswamy et al., 2017).
2) PSMD13, proteasome 26S subunit, non-ATPase 13 – Case-control
studies suggest the involvement of PSMD13 in MDD treatment re-
sponse (Wong et al., 2008; Minelli et al., 2015). Individuals with
lower PSMD13 mRNA levels in fibroblasts may have a greater risk
for treatment-resistant depression (Minelli et al., 2015).
3) TYK2, tyrosine kinase 2 – TYK2 gene variations have not been
previously associated with MDD risk or antidepressant response. A
body of literature supports the relevance of IL6 since it was first
reported to be elevated in MDD (Alesci et al., 2005). Binding of IL6
to the IL6 receptor needs to associate with gp130, which associates
Fig. 1. The process used to filter out SNP exomic
variants genotyped with the Illumina®
HumanExome BeadChip-12v1_A to evaluate the role
of rare functional variants in the pharmacogenetics
of antidepressant response as remitters (n = 36)
and non-responders (n = 29). SNPs were discarded
because they were either monoallelic, had more
than two alleles, had a call rate lower than 90%, or
their genotype proportions deviated from the ex-
pected ones as defined by the Hardy-Weinberg
equilibrium theorem, with P-values < 0.05/m (m is
the number of markers included in the analyses), in
both cases and controls. Common variants (allelic
frequency of the minor allele higher than 0.01),
non-exonic, non-functional variants, and tolerated
and conserved variants were theoretically defined
by the use of SIFT, PolyPhen2, MutationTaster, Gerp
++ and phyloP. The remaining 12,718 variants
were used in the rare variant analysis.
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exclusively to TYK2. Both IL6 classic and trans-signaling modes re-
quire TYK2 for downstream signaling (Hibi et al., 1990;
Leitner et al., 2017). Therefore, selective TYK2 inhibition may re-
present a worthwhile target to block pathological IL6 trans-signaling
(He et al., 2019; Kalkman, 2019; Leitner et al., 2017; Menet, 2014).
The soluble gp130 protein is a recombinant derivative that acts as a
specific inhibitor of IL6 trans-signaling, and it has shown efficacy in
preclinical trials of inflammation models in CNS inflammation.
However, the effects of depression models have not been tested.
4) ALG6, ALG6 alpha-1,3-glucosyltransferase – ALG6 mutations have
been associated with congenital disorders with a primary neurolo-
gical presentation, including epilepsy, ataxia, proximal muscle
weakness, limb anomalies. Behavioral disorders included cyclic
behavioral change, with depressive episodes and autistic features
(Morava et al., 2016).
5) CWC22 spliceosome associated protein homolog gene – This gene
located in chromosome locus 2q13.3/(exm) rs16867321, which has
been previously listed to be amongst the top common SNPs likely to
be associated with antidepressant remission (Wong et al., 2014).
CWC22 is required for multiprotein exon junction complex (EJC)
assembly (Barbosa et al., 2012), which forms upstream of exon-exon
junctions that have produced during RNA splicing on mature
mRNAs, and is involved in post-splicing mRNA processing. This
gene is expressed in the CNS, and CWC22 variants significantly
changed eQTL in the hippocampus and other brain areas. CWC22
gene expression was found to be increased in diabetic dorsal root
ganglia, dysregulating Cajal bodies, nuclear substructure involved in
RNA splicing, and impair neuronal function. CWC22 knockdown
was associated with improved outgrowth and the number of
processes in adult sensory neurons (Kobayashi et al., 2017;
Lein et al., 2007). It is pertinent that this gene is expressed in several
regions of the brain; however, further studies are needed to establish
its association with antidepressant response fully, including in-
dependent replication studies.
6) NLRP1, NLR family pyrin domain containing 1 – This gene encodes
for the sensor component of the NLRP1 inflammasome, which is
present in neurons (Kaushal et al., 2015). Inflammasomes are cy-
tosolic multiprotein complexes that respond to pathogens and other
damage-associated signals playing crucial roles in the innate im-
mune response and inflammation. Little is known about the role of
the NLRP1 inflammasome in MDD or antidepressant response;
however, growing evidence has implicated the role of the NLRP3
inflammasome activation in MDD and stress-induced depressive-like
behaviors (Kaufmann et al., 2017; Wong et al., 2016).
7) Olfactory receptors (OR5B17, OR5B2, OR5D18) – Olfaction has long
been postulated to be involved in depression (Croy and
Hummel, 2017; Mac, 1949). Individuals with olfactory loss have an
increased risk of depressive symptoms (Deems et al., 1991;
Temmel et al., 2002). In rodents, olfactory bulbectomy results in
neurochemical changes in the CNS that are suggestive of MDD and
depressive-like behavior (Lumia et al., 1992; Song and
Leonard, 2005; van der Stelt et al., 2005; Yuan and Slotnick, 2014),
which can be reversed with chronic but not acute antidepressant
treatment (Frazer and Morilak, 2005; Grecksch et al., 1997;
Leonard and Tuite, 1981; Uzunova et al., 2004).
Our pathway and network analysis revealed the involvement of
olfactory transduction, signaling pathway and chemical sensory of
Table 1
Rare variant analysis: several genes were significantly associated with MDD treatment remission.
Chr. Start Stop Gene Name KBAC Score (One-Sided) FDR<0.01 Pc-Value (One-Sided) # Markers # Multi-Marker Genotypes
1 171750761 171766856 METTL13 4.79111958 0.001 4 4
4 147628179 147867034 TTC29 7.51030906 0.001 5 10
2 228474806 228498036 C2orf83 6.50475315 0.002 2 8
11 236808 252984 PSMD13 5.36578529 0.002 5 5
13 25742672 25745857 FAM123A 5.12291136 0.002 2 4
16 72152996 72206349 PMFBP1 6.45231158 0.002 3 7
1 100174259 100231349 FRRS1 6.22381351 0.003 2 5
2 180809604 180871780 CWC22 6.67081036 0.003 4 12
14 95883831 95942173 C14orf49 5.84237836 0.003 2 4
6 24495197 24537435 ALDH5A1 3.56923077 0.004 4 6
8 117962512 118188953 SLC30A8 5.67877054 0.004 1 3
11 58125598 58126542 OR5B17 5.54799654 0.004 2 5
5 118788138 118878030 HSD17B4 5.78600942 0.005 4 6
11 58189738 58190786 OR5B2 5.20040434 0.005 2 4
19 10461204 10491248 TYK2 5.87643803 0.005 5 9
1 57320443 57383894 C8A 4.10183042 0.006 4 4
19 16059818 16060768 OR10H4 5.35816149 0.006 3 4
1 179851420 179889211 TOR1AIP1 5.04115332 0.007 2 4
3 58549845 58563491 FAM107A 4.95954573 0.007 3 5
7 77428109 77586821 PHTF2 5.15205008 0.007 1 3
11 12695969 12966284 TEAD1 5.38681903 0.007 1 3
5 72416388 72427644 TMEM171 4.9260008 0.008 1 3
6 116421999 116566853 NT5DC1 3.12307692 0.008 1 2
9 79226292 79521003 PRUNE2 7.38514885 0.008 25 23
9 107509969 107522403 NIPSNAP3A 4.65492397 0.008 1 3
17 26691290 26692265 SEBOX 4.89169491 0.008 2 4
1 63833261 63904233 ALG6 2.87597633 0.009 3 5
1 150480487 150486265 ECM1 4.40944502 0.009 2 3
3 130064359 130203688 COL6A5 8.4624212 0.009 15 29
4 40337469 40356973 CHRNA9 3.89881189 0.009 3 4
12 70047389 70093196 BEST3 4.09028552 0.009 3 4
16 66788879 66835523 CCDC79 4.22956966 0.009 1 3
17 5404719 5487832 NLRP1 5.86664359 0.009 6 10
11 55587106 55588047 OR5D18 3.12307692 0.010 2 3
18 42792947 43263060 SLC14A2 5.32226339 0.010 5 7
The CWC22 gene appears in bold. Abbreviations: Chr, chromosome; KBAC, Kernel-Based Adaptive Cluster method; FDR, false discovery rate. Variants or genes
positions are based on hg19.
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smell, transport of sugars, bile salts and organic acids, metal ions and
amine compounds, regulation of response to cytokine stimulus, and
meiotic cell cycle process. Notably, the central connections of the ol-
factory system are believed to play a significant role in affective be-
havior (see above). Neuroimmune mediation and neuroinflammation
are active areas of investigation in MDD (Angelucci et al., 2005;
Bhattacharya et al., 2016; Jansen et al., 2016; Wong et al., 2008).
Unexpectedly, our analysis showed the involvement of meiotic cell
processes in antidepressant remission. Stress and emotional states may
dysregulate reproductive functioning, as several neurotransmitters can
modulate the hypothalamic-pituitary-gonadal axis and influence sper-
matogenesis or menstrual cycling (Hendrick et al., 2000). The corre-
lation involving antidepressant medication and reproductive outcomes
have been evaluated by sperm alterations and pregnancy outcomes
(Riggin and Koren, 2015). A significant reduction in sperm viability,
motility or volume has been reported for desmethylimipramine, trip-
mipramine, clomipramine (Kurland et al., 1970; Levin et al., 1981;
Maier and Koinig, 1994). Studies also support that selective serotonin
reuptake inhibitors alter semen parameters reversibly, such as de-
creased sperm motility, concentration, sperm morphology or damaged
Fig. 2. Enriched gene ontology (GO) processes. Genes significantly associated with remission were analyzed using the ConsensusPathDB engine. Enriched GO
processes with P≤0.05 are shown.
Table 3
Quantitative gene expression analyses for the CWC22 gene variants in the hippocampus extracted from the Braineac webserver.
rsID Variant Expr ID P-value Allele frequency
N/A chr2:181492520:T_TA 2590216 4.40E-04 N/A
rs16867335 chr2:181458934 2590216 4.40E-04 C = 79.1% T = 20.9%
rs35579320 chr2:181463612 2590216 4.40E-04 T = 79.1% C = 20.9%
rs72884242 chr2:181465486 2590216 4.40E-04 A = 79.1% T = 20.9%
rs6739798 chr2:181465853 2590216 4.40E-04 T = 79.1% C = 20.9%
rs34842451 chr2:181480525 2590216 4.40E-04 T = 79.1% C = 20.9%
rs13424082 chr2:180227865 2590214 4.90E-01 G = 80.3% A = 19.7%
rs13424082 chr2:180227865 2590220 4.20E-04 G = 80.3% A = 19.7%
rs13424082 chr2:180227865 2590207 4.70E-01 G = 80.3% A = 19.7%
Abbreviations: rsID, reference SNP identification number; Expr ID, expression identification; N/A, not available; chr, chromosome. Variants or genes positions are
based on hg19.
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DNA (Koyuncu et al., 2011; Relwani et al., 2011; Safarinejad, 2008;
Tanrikut et al., 2010; Tanrikut and Schlegel, 2007), which may nega-
tively affect men's fertility (Tanrikut and Schlegel, 2007). Recently, in a
cohort of females (N = 1,650) and males (N = 1,608), no anti-
depressant usage in women with active MDD symptoms (N = 72) was
associated with a small increase in pregnancy rates and not associated
with poorer fertility outcomes, in terms of miscarriage and percentage
of live birth (Evans-Hoeker et al., 2018). However, men with active
MDD episodes were less likely to achieve conception. Antidepressant
use in women without current active MDD (N = 73) was associated
with higher first-trimester miscarriage risk; this association was not
shown in women with active MDD. No differences in live birth rates
were shown in any groups of depressed women (Evans-Hoeker et al.,
2018).
In rodent studies, paternal fluoxetine administration decreased
spermatogenesis, sperm motility, and density, and decrease in preg-
nancy numbers and the number of viable fetuses (Alzahrani, 2012;
Bataineh and Daradka, 2007). Citalopram treatment increased DNA
strand breaks and oxidative DNA damage in sperm (Attia and
Bakheet, 2013). A recent study suggests that antidepressants can in-
fluence sperm parameters differently; amitriptyline and venlafaxine
administration respectively weaken and improve sperm parameters in
rodents (Bandegi et al., 2018).
Rare variants are generally defined as variants with MAF < 1% in
the population studied, which makes replication studies very challen-
ging, as allele frequency varies amongst different populations. Two
recent pharmacogenetics of antidepressant studies addressed rare var-
iants in Caucasian and Han Chinese patients. A meta-analysis of
European-ancestry data from the GENDEP-STAR*D (Genome-Based
Therapeutic Drugs for Depression-Sequenced Treatment Alternatives to
Relieve Depression) studies identified significant associations with
variants in the ITGA9 (Integrin A9; rs116692768; P=2.59e-08;
MAF=0.012) and NRXN3 (Neurexin 3; rs76191705; P=1.80e-08;
MAF=0.033) genes with symptom improvement (Fabbri et al. 2018) by
using MAGMA, a comprehensive gene-set analysis of GWAS data, that
determine the combined effect of multiple genetic markers. This asso-
ciation was replicated only for the ITGA9 variant in the PGRN-AMPS
(Pharmacogenomic Research Network Antidepressant Medication
Pharmacogenomic Study) cohort, and no association was replicated in
the NEWMEDS consortium (http://www.newmeds-europe.com)
sample. However, neither of these SNPs adhere to the strict definition of
rare variants. Xu et al. (2020) identified common variants associated
with antidepressant response at a genome-wide significance level (P <
5 × 10−08) at 5 loci (IL1A, GNA15, PPP2CB, PLA2G4C, and GBA; re-
spectively, Interleukin 1A, G protein subunit alpha 15, protein phos-
phatase 2 catalytic subunit beta, phospholipase A2 group IVC, and
glucosylceramidase beta) in Han Chinese patients.
Our results strongly implicate the role of rare functional variants in
antidepressant drug response. They also actively support the assump-
tion that antidepressant drug response is a phenotype of significant
genetic heterogeneity, since we have been able to identify several rare
gene variants that may be associated with remission to antidepressants
in Mexican-American individuals. Recent data from our lab supports
the assumption that populations of European ancestry have drastically
reduced numbers (50% less) of single nucleotide variants and small
deletions and insertions in comparison to Mexican-Americans
(Wong et al., 2017).
4.1. Limitations
The limitations of this clinical study include: 1) antidepressant
blood levels were randomly collected at different times of the day, thus
precluding their use as covariates. 2) There was no placebo arm; it was
ethically problematic to justify a placebo arm because we used two
antidepressant drugs with known efficacies. One week of single-blind
placebo lead-in was given to participants, as it had been determined a
priori that placebo responders would be removed from the study. The
patients knew that they were going to receive one week of placebo at
any point during the study; however, only the staff knew that placebo
was always given in the first week of the study. 3) Our clinical treat-
ment cohort was small; therefore, further replication studies with larger
cohorts are warranted.
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